Papillary Renal Cell Carcinoma Clinical Trial
Official title:
A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)
The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
| Recruiting |
NCT05043090 -
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
|
Phase 3 | |
| Completed |
NCT02489695 -
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT00098618 -
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
|
Phase 2 | |
| Withdrawn |
NCT04603365 -
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04413123 -
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
|
Phase 2 | |
| Completed |
NCT00126503 -
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01767636 -
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03541902 -
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03866382 -
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
|
Phase 2 | |
| Terminated |
NCT02837991 -
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT00335556 -
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
|
Phase 2 | |
| Recruiting |
NCT04981509 -
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
|
Phase 2 | |
| Recruiting |
NCT04071223 -
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
|
Phase 2 | |
| Recruiting |
NCT00898365 -
Study of Kidney Tumors in Younger Patients
|
||
| Recruiting |
NCT06339138 -
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
|
||
| Not yet recruiting |
NCT06146777 -
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
|
Phase 3 |